Objectives: Describe the epidemiology of ovarian cancer. Review the evaluation of a patient
with suspected ovarian cancer. Summarize the treatment options of ovarian cancer. Outline …

Ovarian cancer (OC) is one of the most common malignancies that causes death in women
and is a heterogeneous disease with complex molecular and genetic changes. Because of …

Background Mirvetuximab soravtansine-gynx (MIRV), a first-in-class antibody–drug
conjugate targeting folate receptor α (FRα), is approved for the treatment of platinum …

Ovarian cancer (OC) is a highly malignant gynaecological tumour that has a very poor
prognosis. Pyroptosis has been demonstrated in recent years to be an inflammatory form of …

Abstract Background Stanniocalcin 1 (STC1) plays an integral role in ovarian cancer (OC).
However, the functional role of STC1 in metastasis, lipid metabolism and cisplatin (DDP) …

Background Bladder cancer (BLCA) is a common malignant tumor of the urinary tract, which
is the sixth most common cancer among men. Numerous studies suggested that pyroptosis …

Background Olaparib, the world's first poly ADP-ribose polymerase (PARP) inhibitor
(PARPi), has been approved for treatment of ovarian cancer, breast cancer, pancreatic …

Purpose Evaluate the antitumor activity and safety profile of the combination of mirvetuximab
soravtansine and bevacizumab in patients with platinum-resistant ovarian cancer. Methods …

Background It was reported that tumor heterogeneity and the surrounding tumor
microenvironment (TME) in ovarian cancer affects immunotherapy efficacy and patient …

Immunotherapy has revolutionized cancer treatment, dramatically improving survival rates of
melanoma and lung cancer patients. Nevertheless, immunotherapy is almost ineffective …